BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22866964)

  • 1. Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.
    Lacourcière Y
    Clin Exp Hypertens; 2013; 35(1):50-60. PubMed ID: 22866964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
    White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
    Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
    White WB; Davidai G; Schumacher H
    J Hum Hypertens; 2009 Dec; 23(12):817-25. PubMed ID: 19357698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period.
    White WB; Lacourciere Y; Davidai G
    Am J Hypertens; 2004 Apr; 17(4):347-53. PubMed ID: 15062889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers.
    Fuenfstueck R; Hempel RD; Ansari A; Weidinger G; Klebs S
    Adv Ther; 2005; 22(3):263-77. PubMed ID: 16236687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of randomized head-to-head trials of telmisartan versus other angiotensin II receptor blocker in combination with hydrochlorothiazide for reduction of blood pressure.
    Takagi H; Mizuno Y; Goto SN; Umemoto T;
    Int J Cardiol; 2013 Sep; 167(6):3062-5. PubMed ID: 23200265
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
    Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
    Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valsartan plus hydrochlorothiazide: a review of its use since its introduction.
    Bains J; Smith WB
    Expert Opin Pharmacother; 2011 Aug; 12(12):1975-84. PubMed ID: 21728903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
    [No Abstract]   [Full Text] [Related]  

  • 11. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
    Deeks ED
    Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
    Nixon RM; Müller E; Lowy A; Falvey H
    Int J Clin Pract; 2009 May; 63(5):766-75. PubMed ID: 19392925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of telmisartan alone or in combination with hydrochlorothiazide on morning home blood pressure control: the SURGE 2 practice-based study.
    Redon J; Bilo G; Parati G;
    Blood Press; 2013 Dec; 22(6):377-85. PubMed ID: 23957824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
    Ma L; Wang W; Zhao Y; Zhang Y; Deng Q; Liu M; Sun H; Wang J; Liu L
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):137-42. PubMed ID: 22329591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors.
    Kjeldsen S; Mancia G; Schmieder R; Mattheus M; Unger T
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):673-82. PubMed ID: 23750676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.
    Duprez DA; Weintraub HS; Cushman WC; Purkayastha D; Zappe D; Samuel R; Izzo JL
    Blood Press Monit; 2011 Aug; 16(4):186-96. PubMed ID: 21747241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
    Weir MR; Levy D; Crikelair N; Rocha R; Meng X; Glazer R
    Am J Hypertens; 2007 Jul; 20(7):807-15. PubMed ID: 17586417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.